| Project/Area Number |
20300179
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical systems
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
NEGISHI Yoichi Tokyo University of Pharmacy and Life Science, 薬学部, 准教授 (50286978)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
新槙 幸彦 (新槇 幸彦) 東京薬科大学, 薬学部, 教授 (90138959)
高木 教夫 東京薬科大学, 薬学部, 准教授 (50318193)
高橋 葉子 (遠藤 葉子) 東京薬科大学, 薬学部, 助手 (30453806)
丸山 一雄 帝京大学, 薬学部, 教授 (30130040)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ARAMAKI Yukihiko 東京薬科大学, 薬学部, 教授 (90138959)
MARUYAMA Kazuo 帝京大学, 薬学部, 教授 (30130040)
TAKAGI Norio 東京薬科大学, 薬学部, 准教授 (50318193)
TAKAHASHI Yoko 東京薬科大学, 薬学部, 助手 (30453806)
|
|---|
| Research Collaborator |
TSUNODA YUKA 東京薬科大学, 薬学部, 大学院生
MATSUO KEIKO 東京薬科大学, 薬学部, 大学院生
DAIKI OMATA 東京薬科大学, 薬学部, 大学院生
HAMANO NOBUHITO 東京薬科大学, 薬学部, 大学院生
MATSUKI YUKI 東京薬科大学, 薬学部, 大学院生
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2010: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2009: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2008: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
|---|
| Keywords | 新生血管 / 超音波造影ガス封入リポソーム / 超音波照射 / 遺伝子治療 / 超音波 / 遺伝子導入 / リポソーム |
|---|
| Research Abstract |
Previously, we have developed polyethyleneglycol (PEG)-modified liposomes entrapping echo-contrast gas, Bubble liposomes (BLs), as a ultrasound-mediated gene delivery tool. In this study, to develop a peptide-modified BLs for angiogenic gene delivery, we prepared the AG73 peptide-modified BLs. AG73-BLs could strongly associate with the bFGF or VEGF-stimulated HUVEC and enhance the gene transfection efficiency into the HUVEC by the combination of US exposure. Furthermore, to make stablely pDNA/BLs complexes, we developed BLs containing DOTAP (DOTAP-BLs) as a cationic lipid and PEG. When bFGF-expressing plasmid DNA/DOTAP-BLs complexes were administrated into ischemic mice model via intravenously and ultrasound was immediately exposed to the ischemic site, the blood flowcould be recovered and angiogenic-related genes could be enhanced. These results suggest that AG73-BLs and DOTAP-BLs may be a useful tool for ultrasound-mediated gene delivery in an angiogenic gene therapy.
|
